Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis

mAbs

Volumn 5, Issue 5, 2013, Pages 655-659

  Challa, Dilip K ^a   Bussmeyer, Uta ^a   Khan, Tarique ^a   Montoyo, Héctor P ^b   Bansal, Pankaj ^a   Ober, Raimund J ^a,c   Sally Ward, E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

^c The University of Texas at Dallas   (United States)

Author keywords

Autoantibody; EAE; Engineered antibodies; FcRn; Therapy

Indexed keywords

ABDEG; ANTIBODY; ANTIGEN; AUTOANTIBODY; FC RECEPTOR; FC RECEPTOR N; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DEPLETION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; FEMALE; LOW DRUG DOSE; MOUSE; NONHUMAN;

AUTOANTIBODY; EAE; ENGINEERED ANTIBODIES; FCRN; THERAPY;

ANIMALS; ANTIBODIES; AUTOANTIBODIES; CHO CELLS; CRICETINAE; CRICETULUS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, FC; RECOMBINANT PROTEINS;

EID: 84883852468     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25439     Document Type: Article

References (36)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204:208-31; PMID:15790361; http://dx.doi.org/10.1111/j.0105-2896.2005.00240.x
2. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol 2012; 7:185-217; PMID:22313379; http://dx.doi.org/10.1146/annurevpathol- 011811-132443
3. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-88; PMID:18272891; http://dx.doi.org/10.1056/NEJMoa0706383
4. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63-70; PMID:16904756; http://dx.doi.org/10.1016/j. jneuroim.2006.06.029
5. Cross AH, Klein RS, Piccio L. Rituximab combination therapy in relapsing multiple sclerosis. Ther Adv Neurol Disord 2012; 5:311-9; PMID:23139702; http://dx.doi.org/10.1177/1756285612461165
6. Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci U S A 2010; 107:4658-63; PMID:20176942; http://dx.doi.org/10.1073/ pnas.1001074107
7. Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 2002; 32:1905-13; PMID:12115610; http://dx.doi. org/10.1002/1521-4141(200207)32:7<1905:: AIDIMMU1905> 3.0.CO;2-L
8. Bansal P, Khan T, Bussmeyer U, Challa DK, Swiercz R, Velmurugan R, et al. The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed towards multiple epitopes in C57BL/6-immunized mice. J Immunol 2013; http://dx.doi.org/10.4049/jimmunol.1300019
9. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-8; PMID:16186811; http://dx.doi.org/10.1038/nbt1143
10. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100:2087-93; PMID:12200371
11. Getman KE, Balthasar JP. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci 2005; 94:718-29; PMID:15682382; http://dx.doi. org/10.1002/jps.20297
12. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 2007; 178:5390-8; PMID:17404325
13. Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A 2008; 105:2337-42; PMID:18272495; http://dx.doi. org/10.1073/pnas.0708960105
14. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30:777-89; PMID:20886282; http://dx.doi.org/10.1007/s10875-010-9468-4
15. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666
16. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 2009; 10:600-14; PMID:19192244; http://dx.doi. org/10.1111/j.1600-0854. 2009.00887.x
17. Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006; 103:18709-14; PMID:17116867; http://dx.doi. org/10.1073/pnas.0606304103
18. Patel DA, Puig-Canto A, Challa DK, Perez Montoyo H, Ober RJ, Ward ES. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol 2011; 187:1015-22; PMID:21690327; http://dx.doi.org/10. 4049/jimmunol.1003780
19. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98:3136-42; PMID:11698302; http://dx.doi. org/10.1182/blood.V98.10.3136
20. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005; 102:13992-7; PMID:16172404; http://dx.doi. org/10.1073/pnas.0504979102
21. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139:4016-21; PMID:3500978
22. Linnington C, Webb M, Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol 1984; 6:387-96; PMID:6207204; http://dx.doi.org/10.1016/0165-5728(84)90064-X
23. Amit AG, Mariuzza RA, Phillips SE, Poljak RJ. Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution. Science 1986; 233:747-53; PMID:2426778; http://dx.doi.org/10.1126/science. 2426778
24. Clynes R. IVIG therapy: interfering with interferongamma. Immunity 2007; 26:4-6; PMID:17241954; http://dx.doi.org/10.1016/j.immuni.2007.01.006
25. Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010; 6:425-34; PMID:20441428; http://dx.doi.org/10.1586/eci.10.9
26. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007; 20:286-93; PMID:17495622; http://dx.doi.org/10.1097/WCO.0b013e3281568b80
27. Haas J, Maas-Enriquez M, Hartung HP. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis-results of a retrospective multicenter observational study over five years. Mult Scler 2005; 11:562-7; PMID:16193894; http://dx.doi. org/10.1191/1352458505ms1224oa
28. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007; 3:120-1; PMID:17342189; http://dx.doi.org/10.1038/ncpneuro0429
29. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110
30. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99; PMID:1560463; http://dx.doi.org/10.1016/0022-2836(92)91010-M
31. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A 2003; 100:9446-51; PMID:12874380; http://dx.doi.org/10.1073/pnas.1133443100
32. Devaux B, Enderlin F, Wallner B, Smilek DE. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J Neuroimmunol 1997; 75:169-73; PMID:9143251; http://dx.doi.org/10.1016/S0165-5728(97)00019-2
33. Lyons JA, San M, Happ MP, Cross AH. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999; 29:3432-9; PMID:10556797; http://dx.doi.org/10.1002/(SICI)1521-4141(199911)29:11<3432::AIDIMMU3432> 3.0.CO;2-2
34. u mice using peptide-MHC multimers. Int Immunol 2000; 12:1553-60; PMID:11058575; http://dx.doi. org/10.1093/intimm/12. 11.1553
35. Kim JK, Tsen MF, Ghetie V, Ward ES. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 1994; 24:2429-34; PMID:7925571; http://dx.doi.org/10. 1002/eji.1830241025
36. Minguela A, Pastor S, Mi W, Richardson JA, Ward ES. Feedback regulation of murine autoimmunity via dominant anti-inflammatory effects of interferon gamma. J Immunol 2007; 178:134-44; PMID:17182548